H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Theravance Biopharma (TBPH) to $20 from $15 and keeps a Buy rating on the shares following the Q3 report. Net sales of Yupelri reached an all-time high of $71.4M, the analyst tells investors in a research note. The firm upped estimates for 2026 and beyond.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH: